Aprepitant versus ondansetron in preoperative triple-therapy treatment of nausea and vomiting in neurosurgery patients: study protocol for a randomized controlled trial

Trials

Soledad Fernandez²  Alejandra Antor¹  Alberto Uribe¹  Adolfo Viloria¹  Sergio Bergese¹ 

[1] Ohio State University Medical Center, N411 Doan Hall, 410W 10th Ave, Columbus, OH, 43210, USA;Ohio State University Medical Center, 2012 Kenny Road, Columbus, OH, 43210, USA

关键词: Postoperative nausea and vomiting;    Ondansetron;    Craniotomy;    Aprepitant;   

Others  :  1095424
DOI  :  10.1186/1745-6215-13-130

 received in 2012-02-17, accepted in 2012-07-16,  发布年份 2012

【 摘 要 】

Background

The incidence of postoperative nausea and vomiting (PONV) is 50% to 80% after neurosurgery. The common prophylactic treatment for postoperative nausea and vomiting is a triple therapy of droperidol, promethazine and dexamethasone. Newer, more effectives methods of prophylaxis are being investigated. We designed this prospective, double-blind, single-center study to compare the efficacy of ondansetron, a neurokinin-1 antagonist, and aprepitant, as a substitute for droperidol, in the prophylactic treatment of postoperative nausea and vomiting after neurosurgery.

Methods

After obtaining institutional review board approval; 176 patients, 18 to 85 years of age with American Society of Anesthesiologists (ASA) classifications I to III, who did not receive antiemetics 24 h before surgery and were expected to undergo general anesthesia for neurosurgery lasting longer than 2 h were included in this study. After meeting the inclusion and exclusion criteria and providing written informed consent, patients were randomly assigned in a 1:1 ratio to one of two treatment groups: aprepitant or ondansetron. The objective of this study was to conduct a randomized, double-blind, double-dummy, parallel-group and single-center trial to compare and evaluate the efficacies of aprepitant versus ondansetron. Patients received oral aprepitant 40 mg OR oral dummy pill within 2 h prior to induction. At induction, a combination of intravenous dexamethasone 10 mg, promethazine 25 mg, and ondansetron 4 mg OR dummy injection was administered. Therefore, all patients received one dummy treatment and three active PONV prophylactic medications: dexamethasone 10 mg, promethazine 25 mg, and either aprepitant 40 mg OR ondansetron 4 mg infusion. The primary outcome measures were the episodes and severity of nausea and vomiting; administration of rescue antiemetic; and opioid consumption for 120 h postoperatively. Standard safety assessments included adverse event reports, physical and laboratory data, awakening time and duration of recovery from anesthesia.

Discussion

The results of this comparative study could potentially identify an improved treatment regimen that may decrease the incidence and severity of postoperative nausea and vomiting in patients undergoing neurosurgery. Also, this will serve to enhance patient recovery and overall satisfaction of neurosurgical patients in the immediate postoperative period.

Trial registration

Registered at The Ohio State University Biomedical Sciences Institutional Review Board: Protocol Number: 2007 H0053

【 授权许可】

   
2012 Bergese et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Gan TJ, Meyer T, Apfel CC, Chung F, Davis PJ, Eubanks S, Kovac A, Philip BK, Sessler DI, Temo J, Tramer MR, Watcha M, Watcha M: Consensus guidelines for managing postoperative nausea and vomiting. Anesth Analg 2003, 97:62-71.
• [2]Audibert G, Vial V: Postoperative nausea and vomiting after neurosurgery (infratentorial and suprtentorial surgery). Ann Fr Anesth Reanim 2004, 23:422-427.
• [3]Basali A, Mascha EJ, Kalfas I, Schubert A: Relationship between perioperative hypertension and intracranial hemorrhage after craniotomy. Anesthesiology 2000, 93:48-54.
• [4]Macario A, Fleisher LA: Is there value in obtaining a patient’s willingness to pay for a particular anesthetic intervention? Anesthesiology 2006, 104:906-909.
• [5]Macario A, Weinger M, Carney S, Kim A: Which clinical anesthesia outcomes are important to avoid? The perspective of patients. Anesth Analg 1999, 89:652-658.
• [6]Gan TJ: Postoperative nausea and vomiting - can it be eliminated? JAMA 2002, 287:1233-1236.
• [7]Manninen PH, Tan TK: Postoperative nausea and vomiting after craniotomy for tumor surgery: a comparison between awake craniotomy and general anesthesia. J Clin Anesth 2002, 14:279-283.
• [8]Apfel CC, Kranke P, Eberhart LHJ, Roos A, Roewer N: Comparison of predictive models for postoperative nausea and vomiting. Br J Anaesth 2002, 88:234-240.
• [9]Murphy MJ, Hooper VD, Sullivan E, Clifford T, Apfel CC: Identification of risk factors for postoperative nausea and vomiting in the perianesthesia adult patient. J Perianesth Nurs 2006, 21:377-384.
• [10]Fortier J, Chung F, Su J: Unanticipated admission after ambulatory surgery: a prospective study. Canadian J Anaesth 1998, 45:612-619.
• [11]Watcha MF, White PF: Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesth 1992, 77:162-184.
• [12]Prommer E, Aprepitant (EMEND): The role of substance P in nausea and vomiting. J Pain Palliat Care Pharmacother 2005, 19:31-39.
• [13]Charbit B, Albaladejo P, Funck-Brentano C, Legrand M, Samain E, Marty J: Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology 2005, 102:1094-1100.
• [14]Kovac AL: Prevention and treatment of postoperative nausea and vomiting. Drugs 2000, 59:213-243.
• [15]Henzi I, Walder B, Tramer MR: Dexamethasone for the prevention of postoperative nausea and vomiting: a quantitative systemic review. Anesth Analg 2000, 90:186-194.
• [16]Harrison S, Geppetti P: Substance P. Int J Biochem Cell Biol 2000, 33:555-576.
• [17]Gan TJ, Kovac A, Lubarsky DA, Phillip BK: PONV Management: Tackling the Practical Issues. CME/CE 2005–2006. http://www.medscape.com/viewprogram/4990 webcite
• [18]Apfel CC, Roewer N, Korttila K: How to study postoperative nausea and vomiting. Acta Anaesthesiol Scand 2002, 46:921-928.
• [19]Gan TJ, Apfel C, Kovac A, Phillip B, Lawson F: The NK1 receptor antagonist aprepitant for prevention of postoperative nausea and vomiting. Anesthesiology 2005, 103:A769.